#Elranatamab hashtag - Bluesky

@hemehub.bsky.social

1 month ago

🩸Facts about Multiple Myeloma:

Frontline Integration

#MultipleMyeloma #Hematology #BispecificAntibodies #StemCellTransplant #ASCT #BsAbs #MRD #ClinicalTrials #Elranatamab #Teclistamab #MajesTEC4 #MajesTEC5 #HemOnc #HEMEHUB

0 0 0 0

@hemehub.bsky.social

1 month ago

🩸 Today’s question focuses on combination therapy evaluated in the MajesTEC-3 trial for relapsed/refractory multiple myeloma (RRMM).

See the answer and explanation on the next slide!

#MultipleMyeloma #Teclistamab #Pomalidomide #Daratumumab #Elranatamab #Carfilzomib #Talquetamab #Hematology

0 0 0 0

@hemehub.bsky.social

2 months ago

🩸Facts about Multiple Myeloma:

Clinical Efficacy and Survival Outcomes

#MultipleMyeloma #BispecificAntibodies #Immunotherapy #Teclistamab #Elranatamab #Daratumumab #ClinicalTrials #Oncology #HematologicMalignancies #CancerTherapy #HEMEHUB

1 0 0 0

@hemehub.bsky.social

2 months ago

🩸Facts about Multiple Myeloma:

Bispecific Antibodies (BsAbs) – Mechanism and Approval

#MultipleMyeloma #RRMM #Hematology #HemOnc #BispecificAntibodies #BsAbs #Immunotherapy #CD3 #BCMA #Teclistamab #Elranatamab #Linvoseltamab #MedEd

0 0 0 0

ilQuaderno.it

@ilquaderno.bsky.social

9 months ago

Mieloma multiplo, un nuovo farmaco in regime di rimborsabilità MILANO (ITALPRESS) – Un nuovo farmaco sviluppato da Pfizer, elranatamab, dà speranza ai pazienti adulti affetti da mieloma multiplo recidivato e refrattario. Dopo l’approvazione di AIFA, l’Agenzia Italiana del Farm...

Mieloma multiplo, un nuovo farmaco in regime di rimborsabilità ... LEGGI TUTTO #MielomaMultiplo #Elranatamab #Pfizer #Salute #FarmaciInnovativi

0 0 0 0

Journal of Comparative Effectiveness Research

@journal-cer.bsky.social

11 months ago

Elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma: an updated matching-adjusted indirect comparison Aim: Despite the availability of novel treatment options for patients with triple-class exposed/refractory multiple myeloma , there is a lack of consensus on the optimal regimen. A previous unanchored...

📢New article alert

New Short Report in JCER finds #elranatamab improves progression-free & overall survival compared to physician's choice of treatment for patients with triple-class exposed/refractory #MultipleMyeloma.

🔗 becarispublishing.com/doi/10.57264...

#Oncology #OpenAccess #JCER

2 1 0 0